Improving immune responses to vaccines using alum adjuvants
Targeting myeloid cells for regulation of alum-based immunity
This study is looking at how alum, a common ingredient in vaccines, helps your immune system make important antibodies that protect your body's surfaces, and it aims to find better ways to deliver vaccines, like through your mouth or nose, so that you can get even stronger protection against infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Ohio State University NIH-funded |
| Lab location | 1 site (Columbus, UNITED STATES) |
| Project ID | NIH-10757682 on NIH RePORTER |
What this research studies
This research investigates how alum, a common vaccine adjuvant, affects the immune system's ability to produce IgA antibodies, which are crucial for protecting mucosal surfaces from pathogens. The study focuses on understanding the role of myeloid cells in regulating these antibody responses. By exploring different methods of vaccine delivery, such as oral or nasal routes, the research aims to enhance the effectiveness of vaccines in generating protective immune responses. Patients may benefit from improved vaccine formulations that better target mucosal immunity.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals who are at risk of infections that enter through mucosal tissues, such as respiratory or gastrointestinal infections.
Not a fit: Patients who do not have a history of mucosal infections or those who are not eligible for vaccination may not receive benefits from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective vaccines that provide better protection against infections at mucosal surfaces.
How similar studies have performed: Previous research has shown promising results in enhancing mucosal immunity through alternative vaccine delivery methods, indicating potential for success in this area.
Where this research is happening
Columbus, UNITED STATES
- Ohio State University — Columbus, United States (Active)
Researchers
- Principal investigator: Boyaka, Prosper N — Ohio State University
- Study coordinator: Boyaka, Prosper N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.